Cite
HARVARD Citation
Wen, F. et al. (2018). OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. BMJ open. 8 (4), p. . [Online].